Skip to Content

A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of ON 01910.Na Concentrate Administered Orally as Escalating Multiple Doses Twice a Day up to 21 Days of a 21-Day Cycle in Patients with Advanced Cancer

Objective
Clinical trial of investigational drug ON 01910.Na given by mouth.
IRB Protocol Number
10-0150
Principal Investigator(s)
ANTONIO JIMENO

Cancer Trials

  • All Cancers
Sponsor(s)
Onconova
Contact
HALEY CHILES at 720-848-5097
or HALEY.CHILES@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are doing well in the study and are willing to continue your participation. A follow up period will consist of a clinic visit after you stop taking the study drug (to follow for any lasting side effects). // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).

Location

  • Clinical Translational Research Center (CTRC)